24 completed, 13 active not recruiting, 5 terminated, 4 recruiting. 35 Phase 2, 29 Phase 1.
Follow Recurrent Non-Hodgkin Lymphoma: new trials by email Literature Review of Recurrent Non-Hodgkin Lymphoma trials Research Report on Recurrent Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma Choline Salicylate, Selinexor - Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 22 | 2021-02-08 | 2026-05-28 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
Showing 20 of 51. Sign in to see all of them.
Lymphoma, Non-Hodgkin (51) · Leukemia, Lymphocytic, Chronic, B-Cell (22) · Hodgkin Disease (20) · Lymphoma, Mantle-Cell (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Lymphoma, Follicular (12) · Neuroblastoma (12) · Osteosarcoma (12) · Hepatoblastoma (11) · Leukemia, Myeloid, Acute (11) · Lymphoma, B-Cell, Marginal Zone (11) · Neuroectodermal Tumors, Primitive, Peripheral (11) · Rhabdomyosarcoma (11) · Wilms Tumor (11) · Ependymoma (10)
Hemic and Lymphatic Diseases (51) · Immune System Diseases (51) · Immunoproliferative Disorders (51) · Lymphatic Diseases (51) · Neoplasms (51) · Neoplasms by Histologic Type (51) · Lymphoproliferative Disorders (50) · Lymphoma (49) · Hematologic Diseases (28) · Chronic Disease (26) · Disease Attributes (26) · Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Leukemia (25) · Leukemia, Lymphoid (24)
Cyclophosphamide (12) · Specimen Handling (9) · fludarabine phosphate (9) · Magnetic Resonance Spectroscopy (8) · CT-P10 (7) · Rituximab (7) · Whole-Body Irradiation (7) · Biopsy (6) · Melphalan (6) · Nivolumab (6) · Peripheral Blood Stem Cell Transplantation (6) · Phantoms, Imaging (6) · X-Rays (6) · Lenalidomide (5) · Mycophenolic Acid (5)
National Cancer Institute (NCI) (20) · M.D. Anderson Cancer Center (8) · Fred Hutchinson Cancer Center (7) · Mayo Clinic (3) · City of Hope Medical Center (2) · Ohio State University Comprehensive Cancer Center (2) · University of Washington (2) · AIDS Malignancy Consortium (1) · Children's Oncology Group (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Sumithira Vasu (1) · University of Nebraska (1) · Virginia Commonwealth University (1)
United States (51) · Puerto Rico (10) · Australia (4) · Canada (3) · Germany (2) · Italy (1)
Sumithira Vasu, MD (2) · Ajay K. Gopal (1) · Alexey Danilov (1) · Amir A Toor, MD (1) · Andrea T Franson (1) · Ariela Noy (1) · Beata Holkova (1) · Brenda Sandmaier (1) · Chelsea C Pinnix (1) · Chitra Hosing (1) · Christine A Pratilas (1) · Crystal L Mackall (1) · David Maloney (1) · Donald W Parsons (1) · Elizabeth D Alva (1)
PMID 31401903, PMID 34515338, PMID 32499241, PMID 21725056, PMID 23834234, PMID 27111235, PMID 27118452, PMID 27410923, PMID 29038338, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31617432, PMID 31648294, PMID 32192573, PMID 32478814, PMID 32967009, PMID 33591402, PMID 33720354, PMID 34320785, PMID 34486544, PMID 34666344, PMID 35353553, PMID 36631449, PMID 37611156, PMID 37774014, PMID 38935895, PMID 39298716, PMID 39333103, PMID 39863139, PMID 41166674, PMID 42389828, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (10), P30CA015704 (5), P50CA097274 (3), N01CM00071 (2), N01CM62201 (2), P01CA018029 (2), P30CA016672 (2), P30CA033572 (2), P50CA107399 (2), UM1CA186717 (2), N01CM00100 (1), N01CM62204 (1), N01CM62208 (1), P01CA078902 (1), P30CA006516 (1)